Myriad Genetics Shares Up 3.6% Over Last 30 Mins As Hearing Piper Jaffray Analyst Suggested A Co. Competitor, Genomind, Resumed Including Specific Drug Recommendations In Physician Reports
Benzinga Newsdesk